Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte
maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian
hyperstimulation syndrome (OHSS) in high-risk patients.
However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH)
level post trigger with single injection of GnRH agonist, which might be related to the
shorter duration and lower amount of LH induced by GnRH agonist.
Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for
preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled
ovarian stimulation in GnRH antagonist protocol.
Phase:
N/A
Details
Lead Sponsor:
Chenshiling
Collaborators:
Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science Comprehensive Strategic Sciences Cooperation Projects of Guangdong Province and Chinese Academy Guangzhou Science and Technology Program key projects National Key Basic Research Development Plan of China National Natural Science Foundation of China